Sotrovimab Use in Young Pediatric Patients at High Risk of Progression to Severe COVID-19 Disease

Abstract

This retrospective analysis describes the administration of sotrovimab in 32 children (22 aged 12–16 years old; 10 aged 1–11 years old) who were at high risk of deterioration to severe COVID-19 disease. We provide dosing suggestions and demonstrate the feasibility of sotrovimab use in the younger pediatric population (<12 years old and <40 kg).